The brain cholinergic system as a target of cognition enhancers

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 1-5

  Giovannini, M G ^a   Casamenti, F ^a   Bartolini, L ^a   Pepeu, G ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

brain; cholinergic system; cognition enhancer; memory

Indexed keywords

NOOTROPIC AGENT; PHOSPHATIDYLSERINE; PYRROLIDINE DERIVATIVE;

ALZHEIMER DISEASE; BRAIN; COGNITIVE DEFECT; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL;

EID: 0031081291     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86038-X     Document Type: Conference Paper

References (69)

1. [1] Bartolini, L., Casamenti, F. and Pepeu, G., Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions, Pharmacol. Biochem. Behav., 53 (1996) 277-283.
2. [2] Bartus, R.T., Dean, R.L., Beer, B. and Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction, Science, 217 (1982) 408-417.
3. [3] Becker, R.E. and Giacobini, E., Mechanisms of cholinesterase inhibition in senile dementia of Alzheimer type: clinical, pharmacological, and therapeutic aspects, Drug Dev. Res., 12 (1988) 163-195.
4. [4] Casamenti, F., Scali, C. and Pepeu, G., Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study, Eur. J. Pharmacol., 194 (1991) 11-16.
5. [5] Collerton, D., Cholinergic function and intellectual decline in Alzheimer's disease, Neuroscience, 19 (1986) 1-28.
6. [6] Copani, A., Genazzani, A., Aleppo, G., Casabona, G., Canonico, P.L., Scapagnini, U. and Nicoletti, F., Nootropic drugs positively modulate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures, J. Neurochem., 58 (1992) 1199-1204.
7. [7] Corwin, J., Dean, R.L., Bartus, R.T., Rotrosen, J. and Watkins, D.L., Behavioral effects of phosphatidylserine in the aged Fisher 344 rats: amelioration of passive avoidance deficits without changes in psychomotor task performance, Neurobiol. Aging, 6 (1985) 11-15.
8. [8] Crook, T.H., Tinkleberg, J., Yesavage, J., Petrie, W., Nunzi, M.G. and Massari, D.C., Effects of phosphatidylserine in age-associated memory impairment, Neurology, 41 (1991) 644-649.
9. [9] Cumin, R., Bandle, E.F., Gamzu, E. and Haefely, W.E., Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents, Psychopharmacology, 78 (1982) 104-111.
10. [10] Davis, K.L., Thal, L.J., Gamze, E.R., Davis, C.S., Woolson, R.F., Gracon, S.I., Drachman, D.A., Schneider, L.S., Whitehouse, P.J., Hoover, T.M., Morris, J.C., Kawas, C.H., Knopman, D.S., Earl, N.L., Kumar, V. and Doody, R.S., A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, New Engl. J. Med., 327 (1992) 1253-1259.
11. [11] Dunnett, S.B., Evenden, J.L. and Iversen, S.D., Delay-dependent short-term memory deficits in aged rats, Psychopharmacology, 96 (1988) 174-189.
12. [12] Durkin, T., Central cholinergic pathways and learning and memory processes: presynaptic aspects, Comp. Biochem. Physiol., 93A (1989) 273-280.
13. [13] Ennaceur, A., Cavoy, A., Costa, J.C. and Delacour, J., A new one-trial test for neurobiological studies of memory in rats. II: effects of piracetam and pramiracetam, Behav. Brain Res., 33 (1989) 197-207.
14. [14] Ennaceur, A. and Delacour, J., A new one trial test for neurobiological studies of memory in rats. 1. Behavioral data, Behav. Brain Res., 31 (1988) 47-59.
15. [15] Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowsky, C.H. and Dolan-Ureno, J., A controlled trial of tacrine in Alzheimer's disease, J. Am. Med. Assoc., 268 (1992) 2523-2529.
16. [16] Gallagher, M. and Pelleymounter, M., Spatial learning deficits in old rats: a model for memory decline in aged, Neurobiol. Aging, 9 (1988) 549-556.
17. [17] Giovannelli, L., Casamenti, F., Scali, C., Bartolini, L. and Pepeu, G., Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis, Neuroscience, 66 (1995) 781-792.
18. [18] Giovannini, M.G., Rodinò, P., Mutolo, D. and Pepeu, G., Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo, Drug Dev. Res., 28 (1993) 503-509.
19. [19] Giurgea, C. and Salama, M., Nootropic drugs, Progr. Neuropsychopharmacol. Biol. Psychiatry, 1 (1977) 235-247.
20. [20] Gouliaev, A.H. and Senning, A., Piracetam and other structurally related nootropics, Brain Res. Rev., 19 (1994) 180-222.
21. [21] Gray, J. and McNaughton, N., Comparison between the behavioural effects of septal and hippocampal lesions: a review, Neurosci. Biobehav. Rev., 7 (1983) 119-188.
22. [22] Hanin, I. and Pepeu, G. (Eds.), Phospholipids. Biochemical, Pharmaceutical and Analytical Considerations, Plenum Press, New York, 1990.
23. [23] Ingram, D.K., Analysis of Age-related impairment in learning and memory in rodent models. In: D.S. Olton, E. Gamzu and S. Corkin (Eds.), Memory Dysfunctions: an Integration of Animal and Human Research from Preclinical and Clinical Perspectives, Vol. 444, New York Academy of Sciences, New York, 1985, pp. 312-331.
24. [24] Ito, I., Tanabe, S., Kohda, A. and Sugiyama, H., Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam, J. Physiol. (Lond.), 424 (1990) 533-543.
25. [25] Izquierdo, I., Mechanism of action of scopolamine as an amnesic, Trends Pharmacol. Sci., 10 (1989) 175-177.
26. [26] Katzman, R., Alzheimer's disease, New Engl. J. Med., 314 (1986) 964-973.
27. [27] Lindner, M., Balch, A.H. and VanderMaelen, C.P., Short forms of the 'reference-' and 'working-memory' Morris water maze for assessing age-related deficits, Behav. Neural Biol., 58 (1992) 94-102.
28. [28] Lo Conte, G., Bartolini, L., Casamenti, F., Marconcini-Pepeu, I. and Pepeu, G., Lesions of cholinergic forebrain nuclei: changes in avoidance behavior and scopolamine actions, Pharmacol. Biochem. Behav., 17 (1982) 933-937.
29. [29] Magnani, M., Pozzi, O., Biagetti, R., Banfi, S. and Dorigotti, L., Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze, Psychopharmacology, 106 (1992) 175-178.
30. [30] Markram, H. and Segal, M., Acetylcholine potentiates responses to N-methyl-D-aspartate in the rat hippocampus, Neurosci. Lett., 113 (1990) 62-65.
31. [31] Messamore, E., Warpman, U., Ogane, N. and Giacobini, E., Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex, Neuropharmacology, 32 (1993) 745-750.
32. [32] Mohs, R.C., Davis, B.M., Johns, C.A. et al., Oral physostigmine treatment of patients with Alzheimer's diesease, Am. J. Psychiatry, 142 (1985) 28-33.
33. [33] Mondadori, C. and Häusler, A., Aldosterone receptors are involved in the mediation of the memory-enhancing effects of piracetam, Brain Res., 524 (1990) 203-207.
34. [34] Murray, T.K., Cross, A.J. and Green, A.R., Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats, Psychopharmacology, 105 (1991) 134-136.
35. [35] Paoli, F., Spignoli, G. and Pepeu, G., Oxiracetam and D-pyroglutamic acid antagonize a disruption of passive avoidance behaviour induced by the N-methyl-D-aspartate receptor antagonist 2-amino-5-phosphonovalerate, Psychopharmacology, 100 (1990) 130-131.
36. [36] Pedata, F., Giovannelli, L., Spignoli, G., Giovannini, M.G. and Pepeu, G., Phosphatidylserine increases acetylcholine release from cortical slices in aged rats, Neurobiol. Aging, 6 (1985) 337-339.
37. [37] Pedata, F., Moroni, F. and Pepeu, G., Effects of nootropic agents on brain cholinergic mechanisms, Clin. Neuropharmacol., 7 (1984) S772-S773.
38. [38] Pedata, F., Slavikova, Y., Kotas, A. and Pepeu, G., Acetylcholine release from rat cortical slices during postnatal development and aging, Neurobiol. Aging, 4 (1983) 31-35.
39. [39] Pepeu, G., Memory disorders: novel treatment, clinical perspective, Life Sci., 55 (1994) 2189-2194.
40. [40] Pepeu, G., Casamenti, F., Scali, C. and Jeglinski, W., Effect of serine phospholipids on memory and brain cholinergic mechanisms in aging rats, Neurosci. Res. Comm., 13, Suppl. 1 (1992) S63-S66.
41. [41] Pepeu, G. and Giovannelli, L., The central cholinergic system during aging. In: F.E. Bloom (Ed.), Neuroscience: from the Molecular to the Cognitive. Progress in Brain Research, Vol. 100, Elsevier, Amsterdam, 1994, pp. 67-71.
42. [42] Pepeu, G., Giovannini, M.G., Casamenti, F., Scali, C. and Rodinò, P., Activation of the brain cholinergic system by noncholinomimetic agents. In R. Becker and E. Giacobini (Eds.), Cholinergic Basis for Alzheimer Therapy, Birkhäuser, Boston, 1991, pp. 200-205.
43. [43] Pepeu, G., Gori, G. and Bartolini, L., Pharmacological and therapeutic perspectives on dementia: an experimental approach. In: L. Amaducci (Ed.), Aging of the Brain and Dementia, Raven Press, New York, 1980, pp. 271-274.
44. [44] Pepeu, G. and Spignoli, G., Nootropic drugs and brain cholinergic mechanisms, Progr. Neuro-psychopharmacol. Biol. Psychiatry, 13 (1989) S77-S88.
45. [45] Perry, E.K., Tomlinson, B.E., Blessed, G., Bergman, K., Gibson, P.H. and Perry, R.H., Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia, Br. Med. J., 2 (1978) 1457-1459.
46. [46] Pontecorvo, M.J. and Evans, H.L., Effects of aniracetam on delayed matching-to sample performance of monkeys and pigeons, Pharmacol. Biochem. Behav., 22 (1985) 745-752.
47. [47] Ponzio, F., Pozzi, O., Banfi, S. and Dorigotti, L., Brain entry and direct central pharmacological effects of the nootropic drug oxiracetam, Pharmacopsychiatry, 22 (1989) S111-S113.
48. [48] Pugliese, A.M., Corradetti, R., Ballerini, L. and Pepeu, G., Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices, Br. J. Pharmacol, 99 (1990) 189-193.
49. [49] Pugsley, T.A., Shih, Y.H., Coughenour, L. and Stewart, S.F., Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent, Drug Develop. Res., 3 (1983) 407-420.
50. [50] Raiteri, M., Costa, R. and Marchi, M., Effects of oxiracetam on neurotransmitter release from rat hippocampus slices and synaptosomes, Neurosci. Lett., 145 (1992) 109-113.
51. [51] Riekkinen, P.J., Riekkinen, M., Lahtinen, H., Sirviö, J., Valjakka, A. and Riekkinen, P., Tetrahydroaminoacridine improves passive avoidance retention defects induced by aging and medial septal lesion but not fimbria-fornix lesion, Brain Res. Bull., 27 (1991) 587-594.
52. [52] Sarter, M., Taking stock of cognition enhancers, Trends Pharmacol. Sci., 12 (1991) 456-461.
53. [53] Sarter, M., Hagan, J. and Dudchenko, P., Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I, Psychopharmacology, 107 (1992) 144-159.
54. [54] Sarter, M., Hagan, J. and Dudchenko, P., Behavioral screening for cognition enhances: from indiscriminate to valid testing: Part II, Psychopharmacology, 107 (1992) 461-473.
55. [55] Satoh, M., Ishihara, K., Iwana, T. and Takagi, H., Aniracetam augments, and midazolam inhibits, the long-term potentiation in guinea pig hippocampal slices, Neurosci. Lett., 68 (1987) 216-220.
56. [56] Schindler, U., Preclinical evaluation of cognition enhancing drugs, Progr. Neuro-psychopharmacol. Biol. Psychiatry, 13 (1989) S99-S115.
57. [57] Schindler, U., Rush, D.K. and Fielding, S., Animal models for studying effects on cognition, Drug Dev. Res., 4 (1984) 567-576.
58. [58] Schroeder, F., Role of membrane lipid asymmetry in aging, Neurobiol. Aging, 5 (1984) 323-333.
59. [59] Sharma, A.C. and Kulkarni, S.K., Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice, Progr. Neuro-psychopharmacol. Biol. Psychiatry, 16 (1992) 117-125.
60. [60] SMID Group, Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study, Psychopharmacol. Bull., 24 (1988) 130-142.
61. [61] Spignoli, G. and Pepeu, G., Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia, Eur. J. Pharmacol., 126 (1986) 253-257.
62. [62] Spignoli, G. and Pepeu, G., Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine, Pharmacol. Biochem. Behav., 27 (1987) 491-495.
63. [63] Summers, W.K., Majowski, L.V., Marsh, G.M. and Kling, A., Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheima type, New Engl. J. Med., 315 (1986) 1241-1245.
64. [64] Vannucchi, M.G., Casamenti, F. and Pepeu, G., Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by phosphatidylserine, J. Neurochem., 55 (1990) 819-825.
65. [65] Vannucchi, M.G. and Pepeu, G., Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats, Neurobiol. Aging, 8 (1987) 403-407.
66. [66] Wu, C.W., Bertorelli, R., Sacconi, M., Pepeu, G. and Consolo, S., Decrease of brain acetylcholine release in aging freely-moving rats detected by microdialysis, Neurobiol. Aging, 9 (1988) 357-361.
67. [67] Wurtman, R.J., Magil, S.G. and Reinstein, D.K., Piracetam diminishes hippocampal acetylcholine levels in rats, Life Sci., 28 (1981) 1091-1093.
68. [68] Xiao, W.B., Nordberg, A. and Zhang, X., Effect of in vivo microdialysis of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on the extracellular concentration of acetylcholine in the striatum of anesthetized rats, J. Pharmacol. Exp. Ther., 265 (1993) 759-764.
69. [69] Zanotti, A., Valzelli, L. and Toffano, G., Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats, Psychopharmacology, 99 (1986) 316-321.